pgmL p
0.064 0.084
mRNA caspase-3 Level DecreasepgmL
0.87±1.96 significant for normal distribution p 0.05
significant for variance homogenity p 0.05
Data from Table 2 were analyzed by t-paired test to determine the difference of mRNA Caspase-3 level prechemotherapy and postchemotherapy. T-
paired test result showed a normal and homogeneous data. There was a significant decrease of mRNA Caspase-3 level 0.87±1.96 pgmL, p 0.05.
Phi and Cramer’s V Test was performed to determine the role of post 1st cycle NAC mRNA Caspase-3 level decrease as a negative chemotherapy response
risk in LABC. Data transformation from numeric to categorical was performed. Analysis results is shown in Table 3.
Table 3 Post 1st cycle NAC mRNA Caspase-3 level decrease as a negative chemotherapy
response risk in LABC
Parameter Response
Total Negative
Positive Decreased
Level Yes
31 6
37 No
13 12
25 Total
44 18
62 p
= 0.007; RR = 4.769; CI95 1.473 – 15.438.
Phi and Cramer’s V Correlation Test showed post 1st cycle NAC mRNA
Caspase-3 level decrease as a negative chemotherapy response risk in LABC r=0.343; p=0.007. The Relative Risk RR was 4.796 1.473-15.438; CI 95.
4.4 Apoptosis Index Level Decrease Correlation with Chemotherapy Response Risk
Prechemotherapy and postchemotherapy Apoptosis Index levels were measured to determine the Apoptosis Index level decrease in LABC patients. Data
is shown in Table 4.
Table 4. Data Rata-rata Penurunan Indeks
Apoptosis
pasien LABC
Parameter Prechemotherapy
Postchemotherapy p
Apoptosis Index 148.55000±102.78000
106.29000±128.91000 0.830
p 0.064
0.068 Apoptosis Index
Level Decrease 42.26000±122.53000
significant for normal distribution p 0.05 significant for variance homogenity p 0.05
T-Paired Test was applied to determine the apoptosis index level decrease prechemotherapy and postchemotherapy Table 4. Analysis showed a normal and
homogeneous data distribution. There was a significant apoptosis index level decrease 42.26000±122.53000; p0.05. Phi and Cramer’s V Test was
performed to determine the role of post 1st cycle NAC Apoptosis Index level decrease as a negative chemotherapy response risk in LABC. Data transformation
from numeric to categorical was performed. Analysis results is shown in Table 5.
Tabel 5 Post 1st cycle NAC Apoptosis Index level decrease as a negative chemotherapy
response risk in LABC
Parameter Response
Total Negative
Positive Decreased
Level Yes
35 7
42 No
9 11
20 Total
44 18
62 p
= 0,002; RR = 6,111; CI 95 1,845 - 20,244.
Phi and Cramer’s V Correlation Test showed post 1st cycle NAC Apoptosis Index level decrease as a negative chemotherapy response risk in
LABC r=0.395; p=0.002. The Relative Risk RR was 6.111 1.845-20.244; CI 95.
4.5 Linear Regression Model Construction for Predicting Apoptosis Index and mRNA Caspase-3 Level Decrease in LABC Patients.
A linear regression model was constructed to predict apoptosis index level decrease based on mRNA Caspase-3 level decrease in LABC patients. We found a
correlation between those factors with r=0.012. The result of linear regression analysis was shown in Table 6.
Tabel 6 Linear Regression Analysis on mRNA Caspase-3 with Apoptosis Index
Coefficients
a
Model Unstandardized Coefficients
Standardized Coefficients
t p
B Std. Error
Beta 1
Constant 38.674
17.159 -2.254
.028 Selisisih
-4.109 8.049
-.066 -.510
.012 a. Dependent Variable: selisishapop
Regression equation, therefore can be derived from data of Table 6 as indicates in the following equation:
Apoptosis Index Level Decrease = 38.674 + 4.109 mRNA Caspase-3 Level Decrease
There was a significant linear regression between mRNA Caspase-3 with Apoptosis Index level r=0.012. Data showed that Apoptosis Index level decrease
post first cycle NAC had a linear association with mRNA Caspase-3 level decrease post first cycle NAC in LABC patients r=0.012. Based on the linear
regression analysis, mRNA Caspase-3 level was correlated with apoptosis index level decrease.
5. DISCUSSION 5.1
